Archives
-
HyperScribe T7 High Yield Cy5 RNA Labeling Kit Guide
2026-08-23
Build sensitive fluorescent RNA probes for in situ hybridization, Northern blot hybridization, and RNA–protein condensation studies with tunable Cy5-UTP incorporation. This workflow-focused guide shows how to balance probe yield, fluorescence, hybridization performance, and assay-specific controls.
-
Protease Inhibitors and Light-Induced Stomatal Opening
2026-08-22
Wang et al. used chemical screening to identify protease inhibitors that suppress blue light-induced stomatal opening in Commelina benghalensis. Their results connect several inhibitor treatments to reduced plasma membrane H+-ATPase phosphorylation while leaving phototropin activity and ABA-dependent responses largely unaffected, providing chemical probes for unresolved guard-cell signaling steps.
-
Antiseptics for Burns: Evidence from a Cochrane Review
2026-08-22
The 2017 Cochrane review examined whether topical antiseptics improve healing, prevent infection, or cause harm in people with burns. Its main contribution was a structured comparison of diverse topical strategies and clinically relevant outcomes, while highlighting uncertainty caused by heterogeneous interventions, comparators, and follow-up periods.
-
HyperScribe T7 Cy5 RNA Labeling Kit Guide
2026-08-21
The HyperScribe T7 High Yield Cy5 RNA Labeling Kit is a tunable Cy5 RNA labeling kit for producing fluorescent RNA probes by T7 in vitro transcription. Its Cy5-UTP substitution can be adjusted to balance transcript yield and labeling efficiency, while the referenced lipid-nanoparticle study provides biological context for mRNA detection without validating this kit for therapeutic delivery.
-
ROS-Responsive LNPs for Tumor-Selective mRNA Delivery
2026-08-20
Cai and colleagues developed a combinatorial library of thioketal-containing, ROS-degradable lipids and identified BAmP-TK-12 as a lipid nanoparticle component that preferentially delivers mRNA to tumor cells. Delivery of mRNA encoding the RAS-cleaving bacterial protease DUF5 depleted mutant RAS and produced stronger antitumor activity than a small-molecule RAS inhibitor in the reported models.
-
Nonselective β-Blockade and HCT Engraftment
2026-08-20
The reference study shows that nonselective β-adrenergic receptor inhibitors can delay hematopoietic regeneration after allogeneic hematopoietic cell transplantation, whereas β1-selective inhibition did not produce the same effect in the tested mouse and human settings. Its cross-species comparison links transplant pharmacology with peripheral nerve–stromal signaling and identifies treatment context, graft type, and transplanted cell dose as important variables for interpretation.
-
AS1842856: A Causal Foxo1 Assay Tool
2026-08-19
AS1842856 is a selective Foxo1 inhibitor for dissecting transcriptional control of gluconeogenesis, autophagy, and MSC state. This article presents an assay-centered framework for connecting Foxo1 activity with the iron-dependent KDM4D–PI3K–Akt pathway while avoiding overinterpretation.
-
WZ4003: NUAK1/2 Inhibitor Workflows
2026-08-19
WZ4003 is a selective NUAK1/2 inhibitor for connecting kinase signaling with cell migration, proliferation, invasion, and tau biology. This practical guide translates its target-validation data into reproducible cell-based and brain-slice workflows, with controls and troubleshooting strategies for interpreting pathway-specific effects.
-
Praeruptorin A Targets ERK/MMP1 in HCC Metastasis
2026-08-18
The reference study identifies an antimetastatic action of praeruptorin A in human hepatocellular carcinoma cells that is separable from general cytotoxicity. Its combination of migration and invasion assays with ERK silencing supports an ERK/MMP1 signaling mechanism, while also defining important limits for translating an in vitro finding into liver cancer therapy.
-
LY2886721: Practical BACE1 Inhibition Workflows
2026-08-17
LY2886721 enables controlled BACE1 enzyme inhibition across cellular, neuronal, biomarker, and in vivo Alzheimer’s disease research workflows. This guide emphasizes exposure calibration, amyloid beta reduction, synaptic-function controls, and solubility-aware handling rather than treating maximal inhibition as the sole endpoint.
-
WST-8 Glucose Uptake Assay: Ion-Aware Design
2026-08-17
Learn how the WST-8 Glucose Uptake Assay Kit converts 2-deoxyglucose processing into a quantitative, non-radioactive readout. This guide adds an ion-aware framework for interpreting glucose uptake after peptide-mediated nucleic acid delivery.
-
Inhaled RNA Reconfigures the Lung Cancer Matrix
2026-08-16
The reference study develops an inhalable lipid nanoparticle that co-delivers anti-DDR1 mRNA and PD-L1 siRNA to address both collagen-mediated immune exclusion and checkpoint-driven immunosuppression in lung cancer. Its findings show how local RNA delivery can remodel tumor architecture, improve immune access, and strengthen antitumor activity in orthotopic and metastatic mouse models.
-
Y-27632 Dihydrochloride: ROCK1–PD-L1 Insight
2026-08-15
Y-27632 dihydrochloride is a selective ROCK inhibitor that can do more than alter cell shape. This article shows how to use it as a causal probe for the DR5–ROCK1–PD-L1 axis while separating cytoskeletal, viability, invasion, and immune-evasion readouts.
-
Carbapenemase Transmission in CREC, 2022–2024
2026-08-14
Chen et al. provide an integrated analysis of carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae from eight teaching hospitals in Guangdong. By combining gene localization, antimicrobial susceptibility testing, conjugation, mobile-element profiling, and strain typing, the study clarifies how blaNDM−1-dominated resistance can disseminate through both plasmid-mediated transfer and clonal spread.
-
CSBTA Pharmacokinetics in MASH Mice
2026-08-14
The reference study shows that MASH-like pathology substantially alters the exposure, liver distribution, and hepatocyte accumulation of dehydrocavidine, palmatine, and berberine from Corydalis saxicola Bunting total alkaloids. By integrating UHPLC-MS/MS profiling with transporter, microsomal metabolism, and PXR-related experiments, it links disease-associated pharmacokinetic variability to coordinated changes in CYP450 enzymes and drug transporters.